Portal de Periódicos da CAPES

Combining Photothermal‐Photodynamic Therapy Mediated by Nanomaterials with Immune Checkpoint Blockade for Metastatic Cancer Treatment and Creation of Immune Memory

2021; Wiley; Volume: 31; Issue: 29 Linguagem: Inglês

10.1002/adfm.202010777

1616-3028

Rita Lima‐Sousa, Bruna L. Melo, Cátia G. Alves, André F. Moreira, António Mendonça, Ilídio J. Correia, Duarte de Melo‐Diogo,

Cancer Immunotherapy and Biomarkers

Abstract The pursuit of effective treatments for metastatic cancer is still one of the most intensive areas of research in the biomedical field. In a not‐so‐distant past, the scientific community has witnessed the rise of immunotherapy based on immune checkpoint inhibitors (ICIs). This therapeutic modality intends to abolish immunosuppressive interactions, re‐establishing T cell responses against metastasized cancer cells. Despite the initial enthusiasm, the ICIs were later found to be associated with low clinical therapeutic outcomes and immune‐related side effects. To address these limitations, researchers are exploring the combination of ICIs with nanomaterial‐mediated phototherapies. These nanomaterials can accumulate within the tumor and produce, upon interaction with light, a temperature increase (photothermal therapy) and/or reactive oxygen species (photodynamic therapy), causing damage to cancer cells. Importantly, these photothermal‐photodynamic effects can pave the way for an enhanced ICI‐based immunotherapy by inducing the release of tumor‐associated antigens and danger‐associated molecular patterns, as well as by relieving tumor hypoxia and triggering a pro‐inflammatory response. This progress report analyses the potential of nanomaterial‐mediated photothermal‐photodynamic therapy in combination with ICIs, focusing on their ability to modulate T cell populations leading to an anti‐metastatic abscopal effect and on their capacity to generate immune memory that prevents tumor recurrence.